ACAnita dos Santos Cardoso

Anita dos Santos Cardoso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anita dos Santos Cardoso has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diabetes Mellitus Gestacional: Rastreio, Diagnóstico e Manejo Terapêutico, Revisão Integrativa da Literatura

    by Anita Cardoso, Emanuelle Santos, Glória Külzer, Maria Clara Prado, Maria Victória Vilarinho, Luiza Cadore, Evelynn Melo

    Objetivo: Analisar criticamente e sintetizar as evidências científicas atuais sobre rastreio, diagnóstico e manejo terapêutico do diabetes mellitus gestacional (DMG). Método: Revisão integrativa da literatura, com buscas nas bases PubMed, Biblioteca Virtual em Saúde (BVS) e SciELO, realizadas entre 6 e 13 de janeiro de 2026, incluindo publicações de 2021 a 2026. Após triagem por dois revisores independentes, com apreciação de divergências por um terceiro pesquisador, 9 estudos foram incluídos na análise final. Resultados: O teste oral de tolerância à glicose permanece o principal método diagnóstico, embora estratégias diagnósticas mais sensíveis nem sempre se traduzam em melhora proporcional dos desfechos clínicos. No tratamento, a insulina segue como referência, mas a metformina, outros agentes orais e terapias adjuvantes, como probióticos e simbióticos, mostram-se alternativas promissoras para o manejo individualizado. Conclusão: O cuidado da DMG deve ser compreendido como um continuum, no qual perfil glicêmico, características clínicas maternas e parâmetros fetais orientam a intensidade terapêutica, ainda que a heterogeneidade metodológica dos estudos disponíveis limite conclusões definitivas.

  • Open Access

    CÂNCER DE PULMÃO EM MULHERES

    by Maria Eduarda Pierini Medeiros, Vitória Lehmkuhl Baggio, Lara Beltrame Camilo, Lara Gomes Ronconi, Anita Dos Santos Cardoso, Juliana Lorenzoni Althoff

    O câncer de pulmão na população feminina tem se destacado pelo aumento de sua incidência nas últimas décadas, em parte relacionado a mudanças nos hábitos de vida e à exposição a fatores de risco, especialmente o tabagismo. Assim, o objetivo do estudo foi analisar os casos de câncer de pulmão em mulheres atendidas em um hospital de alta complexidade entre 2020 e 2023. Trata-se de um estudo observacional, analítico, transversal e retrospectivo, com coleta de dados secundários a partir de prontuários eletrônicos. Os dados foram analisados com auxílio do software IBM SPSS, versão 23.0. Foram avaliados 98 registros de mulheres diagnosticadas com câncer de pulmão em um hospital do Sul do Brasil durante quatro anos. Observou-se aumento no número de diagnósticos no período estudado. Entre os casos com tipo histológico definido, 77,2% corresponderam a carcinoma de não pequenas células e 22,8% a carcinoma de pequenas células. Na distribuição histológica detalhada, o adenocarcinoma foi o subtipo mais frequente, representando 58,7% dos casos com histologia definida, seguido pelo carcinoma de pequenas células, com 22,8%, e pelo carcinoma epidermoide, com 14,1%. Além disso, 68,0% das pacientes apresentavam estágio clínico IV ao diagnóstico. Houve associação estatisticamente significativa entre tabagismo e carcinoma epidermoide e ausência de tabagismo e adenocarcinoma. Também foi observada piora progressiva do estágio clínico ao diagnóstico, com estágios mais avançados nos últimos dois anos da pesquisa. A cirurgia foi associada com o estágio clínico II, enquanto a quimioterapia se associou ao estágio clínico III.

  • Open Access

    Bilateral carotid dissection due to Eagle syndrome: case report

    by Anita dos Santos Cardoso, Yago Marcelino Maciel, Ruymara Candal Nogueira, Rafaela Tezza Matiola, Thais Pereira da Rosa, Fernando Topanotti Tarabay, Gregory Vinícius Périco, Brunella Flores Pupo

    Eagle Syndrome (ES), characterized by elongation of the styloid process (ESP), is a rare condition with diverse symptoms. Among its complications, carotid dissection is a significant outcome requiring accurate diagnosis and intervention. This study describes a case of bilateral carotid dissection associated with ES, emphasizing diagnostic challenges, management, and therapeutic approaches. Conducted under Research Ethics Committee protocol 68193123.5.0000.0119 and approval number 6.028.970, it reports on a 38-year-old woman with a 5-day history of left-sided headache, otalgia, syncope, right-hand limitation, and visual blurring. MRI revealed left carotid bulb occlusion and recent ischemic events, while angio-CT confirmed bilateral carotid dissections. After clinical management failed, an intraoral surgical approach was chosen, resulting in full neurological recovery. CT confirmed ESP, and genetic testing was negative. This case highlights the need to consider ES in atypical cervicofacial symptoms, given its underdiagnosed incidence (~4% for ESP; ~0.16% for ES), reinforcing the importance of better clinical guidelines.

  • Open Access

    Functional constipation in pediatric patients: an observational study in southern Brazil

    by Anita dos Santos Cardoso, Laura Bittencourt de Oliveira, Mayra Sonego

    BACKGROUND: Functional constipation is characterized by a set of symptoms including hardened stools, abdominal discomfort, a tendency to retain stools, and eventual fecal incontinence. This condition negatively affects the quality of life of the affected individuals and has potential psychosocial repercussions. OBJECTIVES: To assess the epidemiological, clinical, and therapeutic aspects of functional constipation in patients treated at a pediatric gastroenterology outpatient clinic. DESIGN AND SETTING: Descriptive observational study with a quantitative approach using secondary data collected from the medical records of a pediatric gastroenterology outpatient clinic in Criciúma between 2018 and 2023. METHODS: This study was approved by the Human Research Ethics Committee of the Universidade do Extremo Sul Catarinense (Unesc) under number 6.788.465. Sociodemographic, clinical, and therapeutic variables were evaluated in 67 patients aged 0–18 years who were diagnosed with Functional Constipation (ICD K590) during the study period. Data were analyzed using descriptive statistics in the Statistical Package for the Social Sciences (SPSS), version 25.0. RESULTS: There was a predominantly female profile (36; 53.7%), with an average age at diagnosis of 7.75 years (± 3.96). The main symptoms included abdominal pain (52, 77.6%) and hardened stools (42, 62.7%), with an average interval of 4 days between bowel movements. Treatment consisted of macrogol prescriptions (60, 89.6%), with most patients showing complete symptom improvement (49, 73.1%). CONCLUSION: Analysis of medical records highlighted the need for continuous monitoring and targeted interventions, considering the variability of symptoms and individual characteristics of patients.


  • Open Access

    Constipação Funcional Pediátrica: Epidemiologia, Diagnóstico e Estratégias Terapêuticas

    by Anita dos Santos Cardoso, Laura Bittencourt De Oliveira, Julia Gatto De Oliveira, André de Abreu Guilherme Raimundo, Eduarda Deluca Müller, Julia Marchiori Romero, Vanessa Caldardo Lemes Da Silva, Yago Marcelino Maciel, Cintia Tomaz Rosa, Camille Teza Vilain, et al.

    A constipação funcional (CF) é um distúrbio gastrointestinal funcional caracterizado por evacuações difíceis e pouco frequentes, com impacto na qualidade de vida infantil. Este estudo é uma revisão sistemática realizada nas bases PubMed, SciELO e BVS Periódicos, incluindo artigos publicados entre 2010 e 2024. Foram selecionados estudos em português, inglês e espanhol que abordassem aspectos clínicos e epidemiológicos da CF. A constipação funcional é a causa mais comum de constipação em crianças, com maior incidência entre 2 e 4 anos, período do desfralde. Sua prevalência varia conforme fatores culturais e ambientais. Estudos indicam maior risco em crianças alimentadas com fórmula, sedentárias e com baixa ingestão de fibras. Distúrbios psicológicos e fatores familiares também influenciam a condição. O diagnóstico segue os critérios Roma IV e deve incluir anamnese detalhada e exame físico, reservando exames complementares para casos específicos. O tratamento baseia-se em quatro etapas: educação, desimpactação, manutenção com laxantes e recondicionamento intestinal. A dieta equilibrada e atividade física são fundamentais para a recuperação. A combinação de mudanças no estilo de vida e uso racional de laxantes melhora o prognóstico e o acompanhamento contínuo das famílias é essencial para evitar recaídas e complicações, promovendo qualidade de vida às crianças afetadas.

  • Open Access

    Congenital Syphilis: Epidemiological Overview in Southeast Brazil

    by Anita Dos Santos Cardoso, Ruymara Candal Nogueira, Higor Braga Cartaxo

    INTRODUÇÃO: A sífilis congênita, doença notificável com estágios clínicos distintos, representa riscos graves para os bebês. A transmissão vertical, especialmente durante os estágios primário e secundário, pode resultar em diversas manifestações clínica e as complicações, se não tratadas, incluem surdez, cegueira e morte fetal. Apesar do papel do rastreamento pré-natal no diagnóstico precoce e tratamento simultâneo de gestantes e parceiros, obstáculos persistem, impactando nos esforços de prevenção primária. OBJETIVO: Analisar a associação entre o cuidado pré-natal inadequado e o tratamento dos parceiros das mulheres grávidas com o aumento dos casos de sífilis. MÉTODOS: Este é um estudo transversal que avaliou os dados do Sistema de Informação de Agravos de Notificação na região sudeste do Brasil, referentes a todos os casos notificados e investigados de sífilis congênita de 2016 a 2021. As variáveis observadas incluíram cuidado pré-natal, tratamento dos parceiros, casos confirmados por ano e estado, educação materna e momento do diagnóstico, sexo, idade, raça dos indivíduos afetados e progressão da doença. RESULTADOS: Entre 2016 e 2021, foram registrados 57.012 casos de sífilis congênita na região sudeste do Brasil. A maioria das mulheres grávidas com bebês afetados por sífilis congênita tinha educação até o ensino médio e recebeu cuidado pré-natal. No entanto, mais da metade dos parceiros não foram tratados adequadamente. CONCLUSÃO: O estudo identificou sérios problemas de saúde pública relacionados à sífilis congênita na região sudeste do Brasil devido à ineficiência das medidas de prevenção e controle. Para enfrentar essa situação, é essencial implementar estratégias como detecção precoce da gravidez, triagem pré-natal, ampla disponibilidade de testes rápidos e capacitação dos profissionais de saúde.


  • OP0181 Treating to Target of Minimal Disease Activity and Normal Function in Polyarticular Juvenile Idiopathic Arthritis with Adalimumab: Analysis from A Phase 3 Clinical Trial

    by N. Ruperto, D. Lovell, P. Quartier, A. Ravelli, M. Karunaratne, J. Kalabic, A. Cardoso, A. Martini, G. Horneff

    Background The Juvenile Arthritis Disease Activity Score (JADAS)1 is becoming widely accepted in juvenile idiopathic arthritis (JIA) for defining a treat to target strategy. Objectives To evaluate the percentage of patients (pts) treated with adalimumab (ADA) (±methotrexate [MTX]) that achieved minimal disease activity (MDA) and both MDA and normalization of function. Methods This post hoc analysis assessed pts aged 4-17 with polyarticular JIA that were enrolled in a phase 3 clinical trial (DE038)2, which consisted of a 16 week (wk) open-label (OL) lead-in with ADA ± MTX, 32wk double-blind (DB) phase with ADA or placebo (PBO)±MTX, and OL extension (OLE) with ADA ± MTX up to 346wks. Clinical and functional outcomes were assessed by 27-joint JADAS (JADAS27), based on C-reactive protein, and Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI). MDA was defined as JADAS27Results At baseline, 75 pts, who had prior MTX, had a mean JADAS27 of 21.2 and CHAQ-DI of 0.9, and 58 pts, who were MTX naïve or had withdrawn from MTX prior to study, had a mean JADAS27 of 23.8 and CHAQ-DI of 1.2. After 16wks of OL ADA, the mean JADAS27 was 6.1 and 6.7 and CHAQ-DI was 0.4 and 0.5 for ADA+MTX and ADA-MTX, respectively, indicating a clinically meaningful change. Clinical improvements were seen at wk48 and wk88, and the mean JADAS27 at wk88 was 2.6, 3.0, 4.3, and 5.0 for ADA+MTX, ADA-MTX, PBO+MTX, and PBO-MTX, respectively, with the greatest improvements seen in ADA continuation. No pts had MDA or normal function at baseline; however, a good proportion achieved MDA and normal function during OL ADA (Table). Fewer pts achieved MDA and normal function in the PBO tx compared with ADA continuation at both wk48 and wk88. Number and percentage of patients achieving minimal disease activity and minimal disease activity with normal function Conclusions ADA, regardless of MTX, resulted in a high percentage of pts achieving and sustaining MDA and normal function. Some improvement was seen in pts treated with PBO during the DB period; however, continued tx with ADA shows better overall clinical and functional outcomes. A target of comprehensive disease control with MDA and normal function is achievable and aligned with current goals of JIA tx. References Consolaro A et al. Arthritis Rheum 2012. Lovell DJ et al. NEJM 2008. Acknowledgements AbbVie sponsored the study (NCT00048542), contributed to design, participated in collection, analysis, interpretation of data, writing, reviewing, and approval of final version. Medical writing was provided by Jessica L. Suboticki, PhD, of AbbVie. Disclosure of Interest N. Ruperto Employee of: GASLINI Hospital, which has received contributions to support the research activities of the network of PRINTO from AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, Janssen Biologics B.V., Eli Lilly and Co., “Francesco Angelini”, GlaxoSmithKline, Italfarmaco, Novartis, Pfizer, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma, and Wyeth Pharmaceuticals, Speakers bureau: Astellas, AstraZeneca, Bristol-Myers Squibb, Italfarmaco, Janssen Biologics B.V., MedImmune, Roche, and Wyeth/Pfizer, D. Lovell Grant/research support: National Institutes of Health – NIAMS, Consultant for: Astra-Zeneca, Centocor, Amgen, Bristol Meyers Squibb, Abbott, Pfizer, Regeneron, Roche, Novartis, UBC, Forest Research Institute, Horizon, and Johnson & Johnson, Speakers bureau: Novartis and Roche, P. Quartier Grant/research support: AbbVie, Novartis, Pfizer, BMS, Chugai-Roche, Medimmune, Servier, and Swedish Orphan Biovitrum, Consultant for: AbbVie, Novartis, Pfizer, BMS, Chugai-Roche, Medimmune, Servier, and Swedish Orphan Biovitrum, A. Ravelli Grant/research support: Pfizer, Consultant for: Hoffman La-Roche, Speakers bureau: Hoffman La-Roche, Centocor, Bristol-Myers Squibb, Pfizer, Novartis and AbbVie Inc, M. Karunaratne Shareholder of: AbbVie, Employee of: AbbVie, J. Kalabic Shareholder of: AbbVie, Employee of: AbbVie, A. Cardoso Shareholder of: AbbVie, Employee of: AbbVie, A. Martini Employee of: GASLINI Hospital, which has received contributions to support the research activities of the network of PRINTO from AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, Janssen Biologics B.V., Eli Lilly and Co., “Francesco Angelini”, GlaxoSmithKline, Italfarmaco, Novartis, Pfizer, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma, and Wyeth Pharmaceuticals, Speakers bureau: Astellas, AstraZeneca, Bristol-Myers Squibb, Italfarmaco, and MedImmune, G. Horneff Grant/research support: AbbVie, Pfizer, and Roche, Speakers bureau: AbbVie, Novartis, Pfizer, and Roche DOI 10.1136/annrheumdis-2014-eular.1600


  • OP0006 Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis

    by G. Horneff, N. Ruperto, C. Wallace, M. Bereswill, A. Cardoso, J. Kalabic, H. Kupper, H. Brunner

    Background Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for use in moderate to severe polyarticular JIA (pJIA) patients (pts) ≥4 years (yrs) in the US, EU, Australia, and Japan, and was recently approved in EU for pts 2 to Objectives To evaluate long-term safety and effectiveness of ADA in pts with moderately to severely active pJIA who are prescribed and treated with ADA in routine clinical practice. Methods This is an ongoing, multicenter, non-interventional, observational registry of pts diagnosed with moderately to severely active pJIA that are prescribed and treated in a routine clinical setting with either ADA ± ethotrexate (MTX) or MTX alone. Approximately 800 pts (500 in ADA arm/300 in MTX arm) will be enrolled in the US, EU, and Australia. The follow-up observational period is 10 yrs from enrollment into one of the treatment arms. For pts that switch from MTX monotherapy to ADA ± MTX, the 10 yr follow-up period will begin when they enroll into the ADA arm. Observational adverse events (AEs) were recorded from the first day in the registry through last contact, irrespective of treatment duration. Clinical outcomes were assessed by 71-joint juvenile arthritis disease activity score (JADAS71). Results As of June 2013, 765 pts (459 in ADA arm/306 in MTX arm) were enrolled and treated. The mean pJIA disease duration at baseline was 1.3 and 3.8 yrs for MTX and ADA arms, respectively. At baseline, there was a mean AJC of 5.8 and disability index of childhood health assessment questionnaire (DICHAQ) of 0.6 for both groups. Overall, 131 pts (42.8%) in the MTX arm and 81 pts (17.6%) in the ADA arm have discontinued registry drug. Of those, 23 (7.5%) and 25 (5.4%) pts in the MTX and ADA arm, respectively, discontinued due to an AE, and 34 out of the 131 pts in the MTX arm discontinued as they switched to the ADA arm. The observational AEs are summarized in the Table. No deaths, malignancies, or opportunistic infections were reported. 12 (2.6%) pts in the ADA arm had a serious infectious AE (including acute tonsillitis, cellulitis, gastroenteritis, mononucleosis, viral meningitis, pneumonia, pyelonephritis, scarlet fever, subcutaneous abscess, tonsillitis, urinary tract infection, and varicella). Frequencies and rates of treatment-emergent AEs were similar to those reported for observational AEs. Mean JADAS71 improved from 13.1 at baseline to 11.2, 6.4, 5.1 at months 1, 3 and 6 for pts in the MTX arm and from 12.1 at baseline to 8.5, 5.7, 5.4 in the ADA arm, respectively (observed data). Overview of Observational Adverse Events (AEs) Conclusions Overall, ADA is well-tolerated in these pts with active pJIA. No new safety signals were observed, and based on this analysis, the known safety profile of ADA remains unchanged. Acknowledgements AbbVie sponsored the study (NCT00783510), contributed to the design, and participated in collection, analysis, and interpretation of data, and in writing, reviewing, and approval of the final version. Medical writing support was provided by Jessica L. Suboticki, PhD, of AbbVie. Disclosure of Interest G. Horneff Grant/research support: AbbVie, Pfizer, and Roche, Speakers bureau: AbbVie, Novartis, Pfizer, and Roche, N. Ruperto Employee of: GASLINI Hospital, which has received contributions to support the research activities of the network of PRINTO from AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, Janssen Biologics B.V., Eli Lilly and Co., “Francesco Angelini”, GlaxoSmithKline, Italfarmaco, Novartis, Pfizer, Roche, Sanofi Aventis, Schwarz Biosciences GmbH, Xoma, and Wyeth Pharmaceuticals, Speakers bureau: Astellas, AstraZeneca, Bristol-Myers Squibb, Italfarmaco, Janssen Biologics B.V., MedImmune, Roche, and Wyeth/Pfizer, C. Wallace Grant/research support: Pfizer and Amgen, Consultant for: Amgen and Novartis, M. Bereswill Shareholder of: AbbVie, Employee of: AbbVie, A. Cardoso Shareholder of: AbbVie, Employee of: AbbVie, J. Kalabic Shareholder of: AbbVie, Employee of: AbbVie, H. Kupper Shareholder of: AbbVie, Employee of: AbbVie, H. Brunner Consultant for: AbbVie Inc., AstraZeneca, Centocor, Bristol-Myers Squibb, Pfizer, Regeneron, Hoffman La-Roche, Novartis, UCB, and Genentech, Speakers bureau: Genentech Pharmaceuticals DOI 10.1136/annrheumdis-2014-eular.1281